New Drug Approval for CLL: An Expert Explains How the Treatment Landscape Is Evolving

Published on

Topics include: Treatment

During this Ask the Expert segment, a Patient Power community member wants to know, “where does the new drug, duvelisib, fit into the chronic lymphocytic leukemia (CLL) treatment landscape?” CLL expert Dr. Jeff Sharman, from The US Oncology Network, responds by explaining how the recently approved medicine works, which drug class it fits into and when it’s appropriate to use in a clinical setting. Watch now to learn more.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc. and Pharmacyclics for their support.

View more programs featuring and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Here's a question that came in based on news events that people follow related to CLL, and this is from William.  He says, I heard there's a new drug approved for CLL, duvelisib.  Can you tell more about this?  Where does it fit in in the CLL landscape?  

It is a—the drug class is a sort of the whole PI3 family of which there's a growing number.  There's idelalisib, umbralisib is in late-stage clinical trials.  Copanlisib (Aliqopa) is approved in follicular lymphoma but not CLL.  And as a family they tend to be utilized less frequently than the BTK inhibitors such as ibrutinib and to some degree less frequently than venetoclax (Venclexta), as well, the Bcl-2 family, and that has to do with some of the side effects, that there is, a frequency of diarrhea, LFT abnormalities and so forth.  So it follows on the heels of idelalisib, and I would say has more similarities than differences.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Understanding the CLL Treatment Landscape: Getting Educated and Speaking Up

CLL patient advocate Mark Silverstein shares tips for others to become a self-advocate while making treatment decisions and communicate effectively with their healthcare team.

Published:

An Expert’s Perspective on the Expanded Approval of Venetoclax

Dr. Susan O’Brien discusses the exciting new data propelling the recent approval for the expanded use of venetoclax and the impact it will have on those living with CLL.

Published:

Genetic Testing for CLL: What Types Are Recommended Before Starting Treatment?

CLL experts Dr. Jackie Broadway-Duren and Dr. Alessandra Ferrajoli discuss what tests can help a CLL patient’s medical team assess disease risk and form a treatment plan. How is a condition’s “report card” determined? Watch now to find out.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on November 29, 2018